AI Article Synopsis
- Capivasertib, combined with fulvestrant, shows antitumor activity in hormone receptor-positive advanced breast cancer, but its cost-effectiveness is uncertain.
- A partitioned survival model evaluated the treatment's cost-effectiveness, revealing an incremental cost-utility ratio (ICUR) of $709,647 per quality-adjusted life-year (QALY) in the US, indicating it is not cost-effective.
- Sensitivity analyses confirmed that factors like overall survival rates and the drug's cost greatly influence these results, and findings for China also suggested the treatment is not cost-effective.
Article Abstract
Objective: Capivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain. This study aimed to evaluate the cost-effectiveness of capivasertib plus fulvestrant versus fulvestrant alone for advanced breast cancer treatment from the perspectives of healthcare payers in the United States. Meanwhile, a experimental analysis from the perspective of China, incorporating specific assumptions, was also conducted in this study.
Methods: A partitioned survival model was constructed to project the progression of breast cancer. Overall survival (OS) and progression-free survival (PFS) data were obtained from the CAPItello-291 trial and extrapolated for long-term survival estimates. Direct medical costs and utility data were gathered. The primary outcome measure was incremental cost-utility ratio (ICUR) to evaluate the cost-effectiveness of treatment regimen. One-way sensitivity analyses (OWSA) and probabilistic sensitivity analyses (PSA) were conducted to assess the robustness of the results.
Results: The base-case analysis estimated the ICUR for capivasertib plus fulvestrant versus fulvestrant alone to be $709,647 per quality-adjusted life-year (QALY) in the US. OWSA revealed that the results were sensitive to hazard ratio of OS and the cost of capivasertib. PSA demonstrated that capivasertib plus fulvestrant exhibited a 0% probability of cost-effectiveness in the US.
Conclusion: Our finding suggests that, at its current price, capivasertib plus fulvestrant regimen is unlikely to be a cost-effective option compared to fulvestrant alone for HR-positive advanced breast cancer patients from the perspective of healthcare system in the US. For the experimental analysis based on specific assumptions from Chinese perspective, the therapy regimen was also found to lack cost-effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774713 | PMC |
| http://dx.doi.org/10.3389/fphar.2024.1495082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.
Front Pharmacol
January 2025
Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai, China.
Article Synopsis
- Capivasertib, combined with fulvestrant, shows antitumor activity in hormone receptor-positive advanced breast cancer, but its cost-effectiveness is uncertain.
- A partitioned survival model evaluated the treatment's cost-effectiveness, revealing an incremental cost-utility ratio (ICUR) of $709,647 per quality-adjusted life-year (QALY) in the US, indicating it is not cost-effective.
- Sensitivity analyses confirmed that factors like overall survival rates and the drug's cost greatly influence these results, and findings for China also suggested the treatment is not cost-effective.
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer.
ESMO Open
December 2024
Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address:
Mutations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway occur in 30%-40% of patients with advanced hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) breast cancer. For most patients, endocrine therapy with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor is the first-line treatment. Recent studies indicate that adding inavolisib, a PI3Kα inhibitor, to palbociclib/fulvestrant benefits patients with endocrine-resistant HR+/HER2- metastatic breast cancer with a PIK3CA mutation.
View Article and Find Full Text PDFTargeted and cytotoxic inhibitors used in the treatment of breast cancer.
Pharmacol Res
December 2024
Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address:
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. Surgery and radiation therapy are localized therapies for early-stage and metastatic breast cancer. The management of breast cancer is determined in large part by the HER2 (human epidermal growth factor receptor 2), HR (hormone receptor), ER (estrogen receptor), and PR (progesterone receptor) status.
View Article and Find Full Text PDFCost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer.
Pharmacoeconomics
December 2024
College of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, R3E0T5, Canada.
Article Synopsis
- Capivasertib is a newly approved, costly drug for advanced breast cancer, leading to an evaluation of its economic value when combined with fulvestrant for specific patient groups.
- A Markov model was used to compare three treatment strategies: adding capivasertib to fulvestrant for all patients, only for postmenopausal women, and using fulvestrant alone, assessing costs and efficacy over a lifetime.
- The study found that adding capivasertib resulted in significantly higher costs ($410,765) with modest additional benefits, making it not cost-effective at its current price when compared to fulvestrant alone.
A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients.
Breast Cancer
December 2024
Division of Endocrine & Breast Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-Cho, Kamigyo-Ku, Kyoto, Japan.
Background: In Japan, despite 5 years since CGP tests were covered by insurance in 2019, low drug accessibility rates remain a critical issue. We evaluated drug accessibility in 3776 breast cancer from the C-CAT database using two criteria: the proportion first linked to PMDA-approved drugs with phase III trial evidence for breast cancer through CGP tests but not existing Companion diagnostics [CDx] (*), and the proportion first linked to PMDA-approved drugs including based on phase I and II trial evidence (**). Additionally, cases linked to investigational drugs for non-PMDA-approved drugs were counted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!